Advertisement
Supported by
By Reuters
FRANKFURT – Biotechnology company BioNTech said on Monday that it has expanded an ongoing global pivot on its COVID-19 candidate vaccine to include evidence in its home country, Germany.
The German vaccine regulator, the Paul Ehrlich Institute, approved the 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and his wife Pfizer said in a statement.
The global test was presented in July, aiming to add approximately 120 international sites and search for up to 30,000 participants in total.
More than 25,000 participants registered, BioNTech said, adding that it was still on track to seek approval from BNT162b2 next month.
(Report via Ludwig Burger; edited through Thomas Seythal)
Advertisement